Produção Nacional
Revisado por pares
New Drugs and Other Strategies for the Treatment of Fungal Infections
2023; Future Medicine; Volume: 18; Issue: 15 Linguagem: Inglês
10.2217/fmb-2023-0169
ISSN1746-0921
AutoresRodrigo Almeida‐Paes, Susana Frasés,
Tópico(s)Fungal Infections and Studies
ResumoFuture MicrobiologyVol. 18, No. 15 ForewordNew drugs and other strategies for the treatment of fungal infectionsRodrigo Almeida-Paes & Susana FrasesRodrigo Almeida-Paes https://orcid.org/0000-0002-6639-6058Laboratório de Micologia, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, 21040-360, BrazilRede Micologia – FAPERJ, Rio de Janeiro, 21941-902, BrazilSearch for more papers by this author & Susana Frases *Author for correspondence: Tel.: +21 3938 6564; E-mail Address: susanafrases@biof.ufrj.brhttps://orcid.org/0000-0001-5875-9886Rede Micologia – FAPERJ, Rio de Janeiro, 21941-902, BrazilLaboratório de Biofísica de Fungos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Cidade Universitária, Ilha do Fundão, Rio de Janeiro, BrasilSearch for more papers by this authorPublished Online:18 Sep 2023https://doi.org/10.2217/fmb-2023-0169AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: antifugal drugsfungimycosesReferences1. Qadri H, Shah AH, Mir M. Novel strategies to combat the emerging drug resistance in human pathogenic microbes. Curr. Drug Targets 22(12), 1424–1436 (2021).Crossref, Medline, CAS, Google Scholar2. Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl. Trop. Dis. 14(2), e0007964 (2020).Crossref, Medline, Google Scholar3. Hoenigl M, Sprute R, Egger M et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 81(15), 1703–1729 (2021).Crossref, Medline, CAS, Google Scholar4. Aggarwal R, Targhotra M, Kumar B, Sahoo PK, Chauhan MK. Treatment and management strategies of onychomycosis. J. Mycol. Med. 30(2), 100949 (2020).Crossref, Medline, CAS, Google Scholar5. Iyer KR, Revie NM, Fu C, Robbins N, Cowen LE. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat. Rev. Microbiol. 19(7), 454–466 (2021).Crossref, Medline, CAS, Google Scholar6. Carpouron JE, de Hoog S, Gentekaki E, Hyde KD. Emerging animal-associated fungal diseases. J. Fungi. (Basel) 8(6), 611 (2022).Crossref, Medline, Google Scholar7. Chaves AFA, Xander P, Romera LMD, Fonseca FLA, Batista WL. What is the elephant in the room when considering new therapies for fungal diseases? Crit. Rev. Microbiol. 47(3), 275–289 (2021).Crossref, Medline, Google Scholar8. Curto MÁ, Butassi E, Ribas JC, Svetaz LA, Cortés JCG. Natural products targeting the synthesis of β(1,3)-D-glucan and chitin of the fungal cell wall. Existing drugs and recent findings. Phytomedicine 88, 153556 (2021).Crossref, Medline, CAS, Google Scholar9. Almeida MA, Bernardes-Engemann AR, Coelho RA et al. Mebendazole inhibits histoplasma capsulatum in vitro growth and decreases mitochondrion and cytoskeleton protein levels. J. Fungi. (Basel) 9(3), 385 (2023).Crossref, Medline, CAS, Google Scholar10. Campoy S, Adrio JL. Antifungals. Biochem. Pharmacol. 133, 86–96 (2017).Crossref, Medline, CAS, Google Scholar11. Souza ACO, Amaral AC. Antifungal therapy for systemic mycosis and the nanobiotechnology era: improving efficacy, biodistribution and toxicity. Front Microbiol. 8, 336 (2017).Crossref, Medline, Google Scholar12. Su S, Yan H, Min L et al. The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy. Expert Rev. Anti. Infect. Ther. 20(2), 161–178 (2022).Crossref, Medline, CAS, Google Scholar13. Zhang J, Lin P, Li J, Guo C, Zhai J, Zhang Y. Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials. Lasers Med. Sci. 37(6), 2557–2569 (2022).Crossref, Medline, Google Scholar14. Kokoska L, Kloucek P, Leuner O, Novy P. Plant-derived products as antibacterial and antifungal agents in human health care. Curr. Med. Chem. 26(29), 5501–5541 (2019).Crossref, Medline, CAS, Google Scholar15. Passero LFD, Cavallone IN, Belda W. Reviewing the etiologic agents, microbe-host relationship, immune response, diagnosis, and treatment in chromoblastomycosis. J. Immunol. Res. 2021, 9742832 (2021).Crossref, Medline, Google Scholar16. Candel FJ, Peñuelas M, Tabares C et al. Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. Rev. Iberoam. Micol. 37(1), 5–16 (2020).Crossref, Medline, Google Scholar17. Teixeira MM, Almeida-Paes R, Bernardes-Engemann AR et al. Single nucleotide polymorphisms and chromosomal copy number variation may impact the Sporothrix brasiliensis antifungal susceptibility and sporotrichosis clinical outcomes. Fungal Genet Biol. 163, 103743 (2022).Crossref, Medline, CAS, Google Scholar18. Shishodia SK, Tiwari S, Shankar J. Resistance mechanism and proteins in Aspergillus species against antifungal agents. Mycology 10(3), 151–165 (2019).Crossref, Medline, CAS, Google Scholar19. Silva DR, Sardi J de CO, Freires IA, Silva ACB, Rosalen PL. In silico approaches for screening molecular targets in Candida albicans: a proteomic insight into drug discovery and development. Eur. J. Pharmacol. 842, 64–69 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 18, No. 15 STAY CONNECTED Metrics Downloaded 20 times History Received 28 July 2023 Accepted 1 August 2023 Published online 18 September 2023 Published in print October 2023 Information© 2023 Future Medicine LtdKeywordsantifugal drugsfungimycosesFinancial & competing interests disclosureThis work was supported by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)